The Food and Drug Administration and the Federal Trade Commission announced this week that they had sent warning letters to three companies that advertised its cannabidiol products as curing or alleviating symptoms of certain diseases.

“This is the first time the FTC has joined in on a warning letter,” said Neil Willner, an associate in the cannabis group at Wilson Elser Moskowitz Edelman & Dicker in White Plains, New York.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]